Q2 Earnings Forecast for Cencora Issued By Leerink Partnrs

Cencora, Inc. (NYSE:COR) – Analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for Cencora in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $4.08 per share for the quarter, down from their prior forecast of $4.23. The consensus estimate for Cencora’s current full-year earnings is $15.36 per share. Leerink Partnrs also issued estimates for Cencora’s Q4 2025 earnings at $3.82 EPS.

Several other research analysts also recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. Wells Fargo & Company increased their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Robert W. Baird boosted their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Stock Performance

COR opened at $246.25 on Monday. The firm has a market cap of $47.59 billion, a P/E ratio of 35.03, a PEG ratio of 1.49 and a beta of 0.49. Cencora has a 1-year low of $214.77 and a 1-year high of $262.26. The company has a 50 day simple moving average of $238.94 and a two-hundred day simple moving average of $236.90. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%.

Institutional Investors Weigh In On Cencora

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dynamic Advisor Solutions LLC boosted its stake in shares of Cencora by 15.2% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock worth $262,000 after purchasing an additional 154 shares during the period. Valeo Financial Advisors LLC lifted its stake in Cencora by 5.0% in the third quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company’s stock worth $370,000 after purchasing an additional 79 shares during the last quarter. Gateway Investment Advisers LLC boosted its position in shares of Cencora by 9.0% during the third quarter. Gateway Investment Advisers LLC now owns 4,388 shares of the company’s stock valued at $988,000 after buying an additional 364 shares during the period. Ritholtz Wealth Management grew its stake in shares of Cencora by 0.8% during the third quarter. Ritholtz Wealth Management now owns 10,560 shares of the company’s stock valued at $2,377,000 after buying an additional 82 shares during the last quarter. Finally, Retirement Planning Group LLC purchased a new stake in shares of Cencora in the third quarter worth approximately $251,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,187 shares of company stock worth $17,790,912. 10.80% of the stock is currently owned by insiders.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio (DPR) is 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.